valsartan has been researched along with Aortic Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, Q; Hu, Z; Liu, C; Pan, C; Ren, X; Yu, YH; Zhao, L | 1 |
| Chu, X; Guo, J; Li, Y; Liu, X; Peng, L; Sun, T; Tang, X; Xu, Q; Yang, X; Yu, H; Zhou, J | 1 |
| Mir, TS; Mueller, GC; Stark, V; Steiner, K; Stierle, L; von Kodolitsch, Y; Weil, J | 1 |
| Bi, X; Li, S; Ma, X; Miao, Y; Su, G; Sun, H; Zhang, W; Zhang, Y; Zhao, Y; Zhong, M | 1 |
| Ameer, OZ; Avolio, AP; Butlin, M; Kaschina, E; Phillips, JK; Sommerfeld, M | 1 |
5 other study(ies) available for valsartan and Aortic Diseases
| Article | Year |
|---|---|
LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Biphenyl Compounds; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Mice; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2020 |
Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hyperplasia; Male; Neointima; Nitric Oxide Synthase Type II; Phosphorylation; Rats, Wistar; Receptor, Angiotensin, Type 1; Serine-Arginine Splicing Factors; Signal Transduction; Toll-Like Receptor 4; Valsartan; Vascular System Injuries | 2021 |
Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Age Factors; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Child; Child, Preschool; Dilatation, Pathologic; Female; Humans; Male; Marfan Syndrome; Metoprolol; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, High-Fat; Fibrosis; Male; Rats, Wistar; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Streptozocin; Thrombospondin 1; Time Factors; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2015 |
Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction, and Structural Remodeling in a Rat Model of Chronic Kidney Disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Blood Pressure; Cathepsin D; Cathepsin L; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hypertension; Kidney; Male; Matrix Metalloproteinase 9; NF-kappa B; Polycystic Kidney Diseases; Rats, Inbred Lew; Renal Insufficiency, Chronic; Time Factors; Valsartan; Vascular Remodeling; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2016 |